- Parkinson's disease (PD) is neuro degenerative disorder which leads to movement associated problems.
- Slow movement is a common side effect to currently available PD drugs including agonists.
- New drug compound, D-512, shows higher efficiency in treatment of early stage PD when compared to regularly administered ropinirole.
A new drug compound, D-512, may
be able to limit the progression of Parkinson's and also relieve its symptoms
when compared to the other currently available drugs. Researchers at Binghamton
University have done a comparative study on rats to evaluate the efficacy of
ropinirole and D-512 in the management of PD symptoms. The study was published
in The British Journal of Pharmacology.
Parkinson's Disease and its Treatment:
Parkinson's disease (PD) is caused due to the depletion of neurons in the part of the brain called the substantia nigra. This part of the brain is associated with control of movement. When the neurons here die, so is the chemical they produce, called dopamine. Loss of dopamine leads to loss of movement.
PD involves the progressive loss of dopamine neurons in the substantia nigra, leading to motor symptoms including:
- Akinesia (Lack Of Movement) Or Bradykinesia (Slow Movement),
- Resting Tremor
- Postural Instability
These drugs have a wide range of side effects including hallucinations and behavioral problems. With long term usage of these drugs, bradykinesia or slow movement is observed in PD patients.
The New Candidate Drug: D-512
To study the anti-parkinsonian properties of the clinically employed ropinirole and the novel D-512, the research team, parkinsonism was simulated in mice and the efficiency of both drug compounds in treating the same were studied. The ability of each drug to stimulate spontaneous motor activity and reverse parkinsonian akinesia was studied.
Highlights of The New Drug Compound:
- High affinity D2/3 receptor agonist and therefore able to attach and mimic effects of dopamine effectively.
- Has antioxidant and neuro-protective properties.
- May have fewer side effects than the currently used medications.
- Has longer duration of action than ropinirole, although both provoked impaired movements. Anti-parkinsonian effects of ropinirole subsided in 2 hours, but that of D-512 lasted for at least 4 hours.
- D-512 was able to reverse forelimb akinesia (lack of movement)
- Rotational behavior, a marker of anti-PD efficacy was greater for D-512 than ropinirole.
- Blood plasma and brain uptake of D-512 was greater than ropinirole.
- Lindenbach, D., Das, B., Conti, M. M., Meadows, S. M., Dutta, A. K., & Bishop, C. (2017). D-512, a novel dopamine D2 / D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over ropinirole in parkinsonian rats. British Journal of Pharmacology. doi:10.1111/bph.13937
- New drug may treat and limit progression of Parkinson's disease - (https://www.eurekalert.org/pub_releases/2017-07/bu-ndm073117.php)
- Parkinson's disease - (http://www.mayoclinic.org/diseases-conditions/parkinsons-disease/basics/treatment/con-20028488)
Please use one of the following formats to cite this article in your essay, paper or report:
Anjali Aryamvally. (2017, August 05). New Drug may Offer Better Symptom Relief and Limit Progression of Parkinson's Disease. Medindia. Retrieved on Aug 13, 2022 from https://www.medindia.net/news/healthinfocus/new-drug-may-offer-better-symptom-relief-and-limit-progression-of-parkinsons-disease-172157-1.htm.
Anjali Aryamvally. "New Drug may Offer Better Symptom Relief and Limit Progression of Parkinson's Disease". Medindia. Aug 13, 2022. <https://www.medindia.net/news/healthinfocus/new-drug-may-offer-better-symptom-relief-and-limit-progression-of-parkinsons-disease-172157-1.htm>.
Anjali Aryamvally. "New Drug may Offer Better Symptom Relief and Limit Progression of Parkinson's Disease". Medindia. https://www.medindia.net/news/healthinfocus/new-drug-may-offer-better-symptom-relief-and-limit-progression-of-parkinsons-disease-172157-1.htm. (accessed Aug 13, 2022).
Anjali Aryamvally. 2021. New Drug may Offer Better Symptom Relief and Limit Progression of Parkinson's Disease. Medindia, viewed Aug 13, 2022, https://www.medindia.net/news/healthinfocus/new-drug-may-offer-better-symptom-relief-and-limit-progression-of-parkinsons-disease-172157-1.htm.